Literature DB >> 20972659

Part I. Development of a model system for studying nitric oxide in tumors: high nitric oxide-adapted head and neck squamous cell carcinoma cell lines.

Yaroslav R Yarmolyuk1, Benjamin J Vesper, William A Paradise, Kim M Elseth, Gabor Tarjan, G Kenneth Haines, James A Radosevich.   

Abstract

The free radical nitric oxide (NO) is over-expressed in many tumors, including head and neck squamous cell carcinomas (HNSCC); however, the role NO plays in tumor pathophysiology is still not well understood. We, herein, report the development of an in vitro model system which can be used to probe the role of NO in the carcinogenesis of HNSCC. Five HNSCC cell lines were adapted to a high NO (HNO) environment by gradually introducing increasing concentrations of DETA-NONOate, a nitrogen-based NO donor, to cell media. The adaptation process was carried out until a sufficiently high enough donor concentration was reached which enabled the HNO cells to survive and grow, but which was lethal to the original, unadapted ("parent") cells. The adapted HNO cells exhibited analogous morphology to the parent cells, but grew better than their corresponding parent cells in normal media, on soft agar, and in the presence of hydrogen peroxide, an oxygen-based free radical donor. These results indicate that the HNO cell lines are unique and possess biologically different properties than the parent cell lines from which they originated. The HNO/parent cell lines developed herein may be used as a model system to better understand the role NO plays in HNSCC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972659     DOI: 10.1007/s13277-010-0101-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  The kinetics and redox state of nitric oxide determine the biological consequences in lung adenocarcinoma.

Authors:  Brandon G Bentz; Neal D Hammer; Brett Milash; Slobodanka Klein; David M Burnett; James A Radosevich; G Kenneth Haines
Journal:  Tumour Biol       Date:  2008-02-05

Review 2.  Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies.

Authors:  Ulrich Förstermann
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-05-06

3.  Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck.

Authors:  B G Bentz; G K Haines; M W Lingen; H J Pelzer; D G Hanson; J A Radosevich
Journal:  Ann Otol Rhinol Laryngol       Date:  1999-08       Impact factor: 1.547

4.  Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide.

Authors:  Benjamin J Vesper; Kim M Elseth; Gabor Tarjan; G Kenneth Haines; James A Radosevich
Journal:  Tumour Biol       Date:  2010-05-18

5.  Serum nitric oxide levels in patients with head and neck squamous cell carcinoma.

Authors:  Ahmet Kizilay; M Tayyar Kalcioğlu; Fikret Ozuğurlu; Hüseyin Ozyurt; Ibrahim Aladağ; Orhan Ozturan; Omer Akyol
Journal:  Kulak Burun Bogaz Ihtis Derg       Date:  2007

6.  Nitric oxide synthase activity in human gynecological cancer.

Authors:  L L Thomsen; F G Lawton; R G Knowles; J E Beesley; V Riveros-Moreno; S Moncada
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

7.  Expression of nitric oxide synthase in human central nervous system tumors.

Authors:  C S Cobbs; J E Brenman; K D Aldape; D S Bredt; M A Israel
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

Review 8.  The multifaceted roles of nitric oxide in cancer.

Authors:  D A Wink; Y Vodovotz; J Laval; F Laval; M W Dewhirst; J B Mitchell
Journal:  Carcinogenesis       Date:  1998-05       Impact factor: 4.944

Review 9.  Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity.

Authors:  W A Pryor
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

10.  Nitric oxide synthase activity in human breast cancer.

Authors:  L L Thomsen; D W Miles; L Happerfield; L G Bobrow; R G Knowles; S Moncada
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  6 in total

1.  Part II-mechanism of adaptation: A549 cells adapt to high concentration of nitric oxide through bypass of cell cycle checkpoints.

Authors:  Madeeha Aqil; Zane Deliu; Kim M Elseth; Grace Shen; Jiaping Xue; James A Radosevich
Journal:  Tumour Biol       Date:  2013-11-17

2.  Part III. Molecular changes induced by high nitric oxide adaptation in human breast cancer cell line BT-20 (BT-20-HNO): a switch from aerobic to anaerobic metabolism.

Authors:  H De Vitto; B S Mendonça; K M Elseth; A Onul; J Xue; B J Vesper; C V M Gallo; F D Rumjanek; W A Paradise; J A Radosevich
Journal:  Tumour Biol       Date:  2012-12-14

3.  Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines.

Authors:  B J Vesper; A Onul; G K Haines; G Tarjan; J Xue; K M Elseth; B Aydogan; M B Altman; J C Roeske; W A Paradise; H De Vitto; J A Radosevich
Journal:  Tumour Biol       Date:  2012-12-14

4.  Part II. Initial molecular and cellular characterization of high nitric oxide-adapted human tongue squamous cell carcinoma cell lines.

Authors:  Gabor Tarjan; G Kenneth Haines; Benjamin J Vesper; Jiaping Xue; Michael B Altman; Yaroslav R Yarmolyuk; Huma Khurram; Kim M Elseth; John C Roeske; Bulent Aydogan; James A Radosevich
Journal:  Tumour Biol       Date:  2010-10-21

5.  A549 cells adapted to high nitric oxide show reduced surface CEACAM expression and altered adhesion and migration properties.

Authors:  Madeeha Aqil; Kim M Elseth; Ashok Arjunakani; Philip Nebres; Courtney P Amegashie; Devang H Thanki; Premal B Desai; James A Radosevich
Journal:  Tumour Biol       Date:  2014-12-11

6.  Part I-mechanism of adaptation: high nitric oxide adapted A549 cells show enhanced DNA damage response and activation of antiapoptotic pathways.

Authors:  Madeeha Aqil; Kim M Elseth; Benjamin J Vesper; Zane Deliu; Bulent Aydogan; Jiaping Xue; James A Radosevich
Journal:  Tumour Biol       Date:  2013-11-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.